Fairview Capital Partners

Inbox Health Corp. is a digital healthcare company based in New Haven, Connecticut, founded in 2014. It specializes in developing a patient communication platform aimed at medical billers in the United States. The Inbox Health platform automates the patient communication process through bi-directional correspondence and utilizes proprietary algorithms, machine learning, and artificial intelligence. This enables patients to better understand their medical bills and access various payment options. By analyzing a wide range of data points across its customer base, the platform allows billers to personalize the billing, payment, and communication experiences for each patient, ultimately enhancing patient collections and overall satisfaction. The company's mission is to reduce administrative waste in healthcare by streamlining the billing and payment experience for patients.

Inbox Health Corp. is a digital healthcare company based in New Haven, Connecticut, founded in 2014. It specializes in developing a patient communication platform aimed at medical billers in the United States. The Inbox Health platform automates the patient communication process through bi-directional correspondence and utilizes proprietary algorithms, machine learning, and artificial intelligence. This enables patients to better understand their medical bills and access various payment options. By analyzing a wide range of data points across its customer base, the platform allows billers to personalize the billing, payment, and communication experiences for each patient, ultimately enhancing patient collections and overall satisfaction. The company's mission is to reduce administrative waste in healthcare by streamlining the billing and payment experience for patients.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.